Head-to-head · WeighScore
Medro vs Royal Medical Center
The verdict
Medro takes it — 63.6/100 to 49.4/100.
Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Medro | Royal Medical Center |
|---|---|---|
| WeighScore | 63.6/100 | 49.4/100 |
| Grade | C | C |
| Scorecard rank | #252 | #492 |
| Semaglutide | $199/mo (compounded) | Not disclosed |
| Tirzepatide | $299/mo (compounded) | $450/mo (2.5 mg dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #252 · C
Strengths
- Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
- LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
- No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
- Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).
Where it loses points
- Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
- Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
- Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
- Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Graded #492 · C
Strengths
- Physician founder Dr. Dagoberto Rodriguez, MD — Emory residency, former Coral Springs Medical Center chairman, U Miami faculty
- Tirzepatide pricing fully itemized by dose tier ($450 / $650 / $800 / $1,100) — more transparent than 'starting at' floors
- All-inclusive pricing bundles medication, supplies, injections, lab monitoring, and physician follow-ups
- Broad catalog (HRT, TRT, peptides, ED, hair, vitamins) reflects an established multi-program clinic
- Florida physician with 30+ years of practice — a strong physician-led care signal
Where it loses points
- Operating legal entity not disclosed — only the 'Royal Medical Center' brand surfaced
- Pharmacy partner not named — buyers can't verify licensure or 503A/503B status
- No LegitScript badge displayed
- States served not enumerated — site says 'nationwide' with no state list
- Headline 'starting at $116/mo' conflicts with the actual $450/mo tirzepatide floor
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.